ProLynx

Name

ProLynx

Legal name

ProLynx LLC

Website

https://prolynxinc.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Drug Delivery)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAAAH

Therapeutic Peptides & Protein/Peptide Biologics

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAIAC

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Drug delivery platforms
• Long-acting therapeutics
• Obesity treatment development
• Metabolic disease therapies
• Biopharmaceutical research

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Therapeutic Development and Commercialization: Prolynx is developing a proprietary portfolio of ultra-long-acting therapeutic candidates targeting once monthly and once-quarterly dosing for obesity and metabolic diseases. The company plans to advance its pipeline toward clinical proof-of-concept and eventual commercialization. As a preclinical biotech, the company is pre-revenue with no commercial products yet.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

ProLynx develops a proprietary hydrogel-based microsphere drug delivery platform that uses tunable release linker chemistry to enable ultra-long-acting peptide therapeutics. The company's pipeline targets once-monthly and once-quarterly dosing for obesity, type 2 diabetes, and other metabolic conditions, with PLX-821 (a long-acting semaglutide) as the lead candidate. ProLynx does not yet have commercial products and is advancing candidates through preclinical development toward IND enablement and clinical proof-of-concept.

Product overview

ProLynx is a biotechnology company developing a next-generation portfolio of ultra-long-acting therapeutics for obesity and related metabolic conditions. The company's offering centers on its proprietary hydrogel-based microsphere platform (tetra-PEG-based) with tunable release linker chemistry, which enables once-monthly and once-quarterly dosing of peptide therapeutics. The lead product is PLX-821 (semaglutide), an ultra-long-acting GLP-1 receptor agonist candidate. The broader pipeline includes dual and triple agonist programs, amylin-based therapies, and combination approaches—all designed to leverage the same extended-duration framework with potential for up to 90-day dosing intervals and pharmacokinetically matched combinations. The technology was previously validated in clinical oncology applications, providing a de-risked foundation for metabolic disease development.

Differentiator

Problem solved

Functional benefit

Products and services

• PLX-821 (semaglutide)

Quantifiable outcome

• Dosing interval extended from weekly to monthly or quarterly administration
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ascendis Pharma: Ascendis Pharma developed TransCon, a prodrug/pro-drug linker platform for long-acting biologics with once-weekly and longer dosing intervals (e.g., TransCon hGH, TransCon PTH). Both companies pursue proprietary linker chemistry to extend half-life of therapeutic peptides/proteins, making Ascendis the closest direct comparable for ProLynx's platform approach.
• Zealand Pharma: Zealand Pharma specializes in peptide-based therapeutics for metabolic diseases, including glepaglutide and dasiglucagon. Both companies focus on engineered peptides for obesity, diabetes, and metabolic conditions, with overlapping target indications and similar pipeline-stage development timelines.
• Halozyme Therapeutics: Halozyme's ENHANZE platform uses a proprietary enzyme (recombinant human hyaluronidase) to enable subcutaneous delivery of biologics with shorter injection times. Both companies are drug-delivery technology platforms licensing to large pharma partners, although Halozyme's mechanism (tissue permeability) differs from ProLynx's sustained-release depot approach.
• Amunix Pharmaceuticals: Amunix developed XTEN, a half-life extension technology for therapeutic proteins and peptides using unstructured polypeptide fusion partners. Acquired by Sanofi in 2021, Amunix pursued a parallel vision of long-acting biologic therapeutics; the technology convergence and acquisition outcome serve as a relevant comparable for ProLynx's strategic trajectory.
• Crinetics Pharmaceuticals: Crinetics develops oral and long-acting peptide therapeutics for endocrine and metabolic diseases, including acromegaly and hyperinsulinism programs. The shared focus on engineered peptide therapeutics for chronic metabolic conditions, plus parallel development of oral and long-acting formulations, makes Crinetics a direct peer in target indication and modality.
• Hanmi Pharmaceutical: Hanmi developed the LAPSCO (Long Acting Protein/Peptide Stabilized Conjugate) platform for sustained-release peptide therapeutics, partnering with Sanofi on efpegerglucagon and other long-acting programs. Both companies apply proprietary conjugation chemistries to extend peptide dosing intervals, with overlapping obesity and metabolic pipelines.

Emerging players

• Carmot Therapeutics: Carmot developed peptide and small-molecule therapeutics for obesity and metabolic disease, including CT-388 (a dual GLP-1/GIP agonist) acquired by Roche in 2023 for $2.7B. Comparable therapeutic focus and dual-agonist program overlap make Carmot a strong peer for ProLynx's next-gen metabolic pipeline ambitions.

Broad incumbents

• Eli Lilly: Eli Lilly markets tirzepatide (Mounjaro/Zepbound), the dominant dual-agonist GLP-1/GIP therapy in obesity and type 2 diabetes, and is developing next-gen oral GLP-1s and triple agonists. As the leading incumbent in the obesity therapeutic space that ProLynx targets, Lilly defines the competitive benchmark ProLynx's PLX-821 must beat.
• Novo Nordisk: Novo Nordisk markets semaglutide (Ozempic/Wegovy), the foundational GLP-1 therapy ProLynx's PLX-821 is reformulating, and is advancing its own oral and next-generation obesity programs. As the originator of semaglutide and category leader in GLP-1 therapies, Novo Nordisk is the most direct large-pharma incumbent ProLynx must compete against or partner with.
• Bristol Myers Squibb: BMS acquired ProLynx co-founder Daniel Santi's previous company Kosan Biosciences, demonstrating the strategic acquirer pattern for delivery-platform biotechs. As a major pharma active in metabolic disease and oncology with a track record of acquiring similar platform companies, BMS represents the most likely large-pharma acquirer or partner archetype for ProLynx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prolynx-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds12 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProLynx